Published by Josh White on 20th October 2025
(Sharecast News) - Faron Pharmaceuticals said on Monday that updated results from its phase one and two 'BEXMAB' study showed further improvement in the clinical performance of bexmarilimab, strengthening the drug's profile as a treatment for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).